Search Patents
  • Isolated nucleic acid molecules which encode SCP proteins
    Patent number: 6214983
    Abstract: The invention involves the recognition of a previously unidentified protein family which belongs to, the human SCP family. The members of the family, such as SCP-2 and rat SCP-3 homolog are markers for cell transformation. Diagnostic and therapeutic uses of these protein and related molecules are taught.
    Type: Grant
    Filed: October 22, 1998
    Date of Patent: April 10, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Isolated nucleic acid molecules encoding SSX family members and thereof
    Patent number: 6291658
    Abstract: The invention relates to members of the SSX family of genes, as well as their uses.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: September 18, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ali O. Gure, Ozlem Tureci, Ugur Sahin, Solam Tsang, Matthew J. Scanlan, Alexander Knuth, Michael Pfreundschuh, Lloyd J. Old, Yao-Tseng Chen
  • Methods and compositions for diagnosis and treatment of cancer
    Patent number: 11473085
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: October 18, 2022
    Assignees: GANYMED PHARMACEUTICALS GMBH, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20200079866
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: September 25, 2019
    Publication date: March 12, 2020
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Cytokine Fusion Proteins
    Publication number: 20180002392
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Application
    Filed: January 15, 2016
    Publication date: January 4, 2018
    Inventors: Ugur Sahin, Friederike Gieseke, Ronald Backer, Sebastian Kreiter, Roland Kontermann, Klaus Pfizenmaier, Sina Fellermaier, Dafne Müller
  • Genetic Products Differentially Expressed In Tumors And The Use Thereof
    Publication number: 20150337052
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Application
    Filed: August 7, 2015
    Publication date: November 26, 2015
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Recombinant vaccines and use thereof
    Patent number: 11298426
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: April 12, 2022
    Assignee: BioNTech SE
    Inventors: Ozlem Tureci, Ugur Sahin, Sebastian Kreiter
  • GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
    Publication number: 20090155817
    Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Application
    Filed: December 3, 2008
    Publication date: June 18, 2009
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • CLAUDIN-6-SPECIFIC IMMUNORECEPTORS AND T CELL EPITOPES
    Publication number: 20220306711
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: April 4, 2022
    Publication date: September 29, 2022
    Inventors: Ugur SAHIN, Özlem TÜRECI, Petra SIMON, Tana OMOKOKO, Holger HOFF, Ralf-Holger VOSS, Andrea BREITKREUZ, Kathleen HOBOHM, Karolina Anna MROZ
  • PREDICTING IMMUNOGENICITY OF T CELL EPITOPES
    Publication number: 20220093209
    Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
  • METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS
    Publication number: 20240110247
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Application
    Filed: June 6, 2023
    Publication date: April 4, 2024
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20210253725
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20180194849
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 12, 2018
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
    Publication number: 20150368723
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Application
    Filed: June 19, 2015
    Publication date: December 24, 2015
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schlüter
  • METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS
    Publication number: 20210324472
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Application
    Filed: December 23, 2020
    Publication date: October 21, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
  • Recombinant vaccines and use thereof
    Publication number: 20100111993
    Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.
    Type: Application
    Filed: October 13, 2004
    Publication date: May 6, 2010
    Inventors: Özlem Türeci, Ugur Sahin, Sebastian Kreiter
  • Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
    Publication number: 20170052187
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 23, 2017
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schluter
  • Genetic products differentially expressed in tumors and the use thereof
    Publication number: 20060035852
    Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. Said invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for said polypeptides, peptides and proteins.
    Type: Application
    Filed: November 21, 2003
    Publication date: February 16, 2006
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Methods and kits for the diagnosis of cancer
    Patent number: 10705089
    Abstract: The present invention relates to methods and kits for the diagnosis, prognosis and/or monitoring of cancer in a patient. The present invention further relates to isolated peptides, panels of isolated peptides and diagnostic devices.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 7, 2020
    Assignees: BioNTech Disgnostics GmbH, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Rainer Hipfel, Clara Werner, Andree Rothermel, Ugur Sahin, Yvonne Kuhne
  • Identification of Tumor-Associated Antigens for Diagnosis and Therapy
    Publication number: 20110189179
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Application
    Filed: April 13, 2011
    Publication date: August 4, 2011
    Inventors: Ugur Sahin, Özlzem Türeci, Michael Koslowski, Dirk Usener
Narrow Results

Filter by US Classification